Laubli Heinz, Borsig Lubor
Zurich Center for Integrative Human Physiology, Institute of Physiology, University of Zurich, Zurich, Switzerland.
Cancer Invest. 2009 Jun;27(5):474-81. doi: 10.1080/07357900802647136.
Heparin is often used to prevent or treat thromboembolism in cancer patients. Clinical and experimental evidence suggest that heparin also has anticancer activities. Experimental evidence consistently supports the ability of heparin to attenuate metastasis. The potential antimetastatic effects of heparin include inhibition of cell-cell interactions and heparanase and modulation of growth factors, and anticoagulant activity. Heparin inhibits selectin-mediated interactions of tumor cells with leukocytes, platelets, and endothelial cells, which are likely to mediate the initial steps of hematogenous metastasis. Prospective clinical trials can be designed on the basis of the insights obtained from experimental studies.
肝素常用于预防或治疗癌症患者的血栓栓塞。临床和实验证据表明，肝素还具有抗癌活性。实验证据一直支持肝素减弱转移的能力。肝素潜在的抗转移作用包括抑制细胞间相互作用、乙酰肝素酶以及调节生长因子和抗凝活性。肝素抑制肿瘤细胞与白细胞、血小板和内皮细胞的选择素介导的相互作用，这些相互作用可能介导血行转移的初始步骤。可根据从实验研究中获得的见解设计前瞻性临床试验。
